Sep. 15, 2016—Researchers at Vanderbilt University Medical Center have discovered a key mechanism that explains how compounds they’re developing can suppress schizophrenia-like symptoms without side effects in mice.
Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.
Mar. 21, 2016—A new compound developed at Vanderbilt treats multiple symptoms of schizophrenia in an animal model, without causing sedation.
Aug. 21, 2015—Functional magnetic resonance imaging has revealed faulty circuits between the thalamus – a central hub of brain activity – and other brain regions.
Jul. 9, 2015—Vanderbilt researchers have discovered a possible molecular mechanism of schizophrenia that could lead to new treatments for the disorder.
Jul. 8, 2015—Applying mild electrical stimulation to an area of the brain associated with cognitive control helps people with schizophrenia to recognize errors and adjust their behavior to avoid them.
Jun. 16, 2015—Vanderbilt investigators report the first use of a specialized type of MRI to study the hippocampus in patients with schizophrenia.
May. 7, 2015—Vanderbilt University researchers have uncovered a surprising finding that could lead to the development of new, more effective therapies for schizophrenia, which affects more than 2 million Americans.
Mar. 19, 2015—There is growing evidence that disorders such as autism and schizophrenia involve deficits in what is called “multi-sensory processing,” the ability of the brain to properly integrate information coming in through the eyes, ears and other senses.
Feb. 12, 2015—Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.
Feb. 12, 2015—Catatonia, a syndrome characterized by muscular rigidity and a trance-like mental stupor, can at times manifest with great excitement and confusion. And while it is often associated with schizophrenia, it can present in patients with either medical or psychiatric conditions. For this reason, the condition has often confused clinicians.
Jan. 23, 2015—Although heteromeric dopamine receptors composed of both D1 and D2 subunits have been proposed to play a role in depression and schizophrenia, recent studies suggest these heteromers do not exist.